Transenterix Inc. has received a nod from the FDA to market the Senhance surgical robotic system. This is the second FDA clearance of a surgical robotic system for abdominal entry since Intuitive Surgical Inc. received FDA clearance for the Da Vinci in 2000. The FDA nod came earlier than the company's year-end expectation. News of the approval caused Morrisville, N.C.-based Transenterix's (NYSEAMERICAN:TRXC) shares to rise as much as 90 percent – closing at $2.81 on Monday.